

## Results of 2015 Annual General Meeting

**Melbourne, Australia, 7 December 2015.** Progen Pharmaceuticals Ltd (ASX: PGL, OTC: PGLA) today releases the results of the 2015 Annual General Meeting.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, the Company advises that the resolutions detailed in the Notice of Meeting were determined as follows:

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain *	Carried / Not Carried
1 Directors' Remuneration Report	Ordinary	17,262,178 99.17%	101,155 0.58%	43,682 0.25%	13,430	Carried on a show of hands			Carried
2 Re-election of Director - Mr Indrajit Arulampalam	Ordinary	17,341,239 99.55%	34,080 0.20%	43,682 0.25%	1,444	Carried on a show of hands			Carried
3 Election of Director - Dr Christopher Harvey	Ordinary	17,354,009 99.63%	21,310 0.12%	43,682 0.25%	1,444	The resolution was withdrawn			N/A

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

**ENDS**

### About Progen Pharmaceuticals Ltd

Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development.  
[www.progen-pharma.com](http://www.progen-pharma.com)

**For more information:**

Blair Lucas  
Company Secretary  
+61 7 3273 9133  
+61 403 358 638

This release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PG545, and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.